FDA clears first migraine DTx from Click Therapeutics

FDA clears first migraine DTx from Click Therapeutics

Click Therapeutics' digital therapeutic (DTx) for migraine prevention has been cleared by the FDA, becoming the first treatment of its type in the US.

Click gets FDA authorization for preventive migraine digital therapeutic

In a sign of life for the digital therapeutics industry, Click Therapeutics has received FDA authorization for its treatment. The FDA has given marketing authorization for Click’s digital therapeutic to preventively treat episodic migraines, the ...

FDA Approves CT-132 as First Digital Therapeutic for Preventive Treatment of Episodic Migraine

CT-132, an approach that aims to reduce brain hypersensitivity, becomes the first marketed digital treatment for preventive migraine, intended to be used with other previously approved medications.

A Digital Turning Point in Migraine Care: CT-132 FDA Approval to Market is a Win for Patients and Proof that Clinical Evidence Matters - Medika Life

Sometimes, when the Food and Drug Administration (FDA) grants marketing authorization for a new treatment, it signals more than regulatory approval, reflecting a moment of transformation for the people who live daily with the disease. This is one of those milestones.  For the more than 37 million Americans who suffer from migraines, the FDA authorization of Click Therapeutics’ CT-132—the first prescription digital therapeutic for the preventive …

FDA Clears Prescription Digital Therapeutic for Migraine Prevention

What You Should Know:  – Click Therapeutics, Inc. (“Click”), a leader in the rapidly evolving field of prescription medical treatments, encompassing both prescription digital therapeutics (PDTs) and software-enhanced drug therapies has received FDA marketing authorization for CT-132, the first prescription digital therapeutic specifically indicated for the preventive treatment of episodic migraine in adults aged 18 and older. – The FDA granted a…